Melanoma,Skin Cancer Before or After: The Debate on Pembrolizumab Administration for High-Risk Melanoma Jun 01, 2023
Melanoma,Skin Cancer Adjuvant Pembrolizumab or Placebo in Stage III Melanoma: 5-Year Analysis May 22, 2023
Melanoma,Skin Cancer CheckMate-915 Study Shows Improved Survival Rates for Resected Stage III/IV Melanoma Patients Apr 20, 2023
Melanoma,Skin Cancer Efficacy of Relatlimab and Nivolumab Combination Therapy Examined in Advanced Melanoma Patients Apr 20, 2023
Melanoma,Skin Cancer Neoadjuvant Immunotherapy and Targeted Therapy in BRAF Mutant Resectable Stage III Melanoma Apr 20, 2023
Melanoma,Skin Cancer Superior Efficacy of Nivolumab Plus Ipilimumab in CheckMate 067 for Advanced Melanoma Apr 20, 2023
Melanoma,Skin Cancer Phase 3 Trial: Pembrolizumab as Adjuvant Therapy for Resected Melanoma Mar 07, 2023
